Drug intelligence / Profile preview

BBT-207

Development stage: Phase 2
Lead developer: Bridge Biotherapeutics
Modality: Small Molecules
Administration: Oral

Overview

BBT-207 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by Bridge Biotherapeutics. It is designed to selectively inhibit EGFR with C797S mutations, as well as other complex EGFR mutations such as T790M and drug-naïve mutants. BBT-207 has shown potent activity and efficacy against a broad range of EGFR mutations in non-small cell lung cancer (NSCLC), particularly in patients who have progressed after treatment with third-generation EGFR TKIs[1][3][4]. The drug is currently being evaluated in Phase 1/2 clinical trials for advanced NSCLC harboring specific EGFR mutations.

Other names: BBT 207BBT207BBT-207

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on BBT-207.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBT-207.

Explore the full profile